thalidomide [Ligand Id: 7327] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL468 (.alpha.-phthalimidoglutarimide, Celgene, Contergan, Distaval, K-17, Myrin, Neurosedyn, N-phthalylglutamic acid imide, NSC-527179, NSC-66847, Pantosediv, Pharmion, Softenon, Talidex, Thaled, Thalidomide, Thalidomide, Thalidomide lipomed, Thalomid)
  • Cereblon isoform 4 in Magnetospirillum gryphiswaldense [ChEMBL: CHEMBL3763007] [UniProtKB: A4TVL0]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
Cereblon isoform 4 in Magnetospirillum gryphiswaldense (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3763007] [UniProtKB: A4TVL0]
ChEMBL Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by Cheng-Prusoff equation analysis B 5.02 pKi 9600 nM Ki J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by Cheng-Prusoff equation analysis B 5.36 pKi 4400 nM Ki J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL Inhibition of MANT-uracil binding to wild-type Magnetospirillum gryphiswaldense CRBN isoform 4 by FRET assay B 5.36 pKi 4400 nM Ki J Med Chem (2019) 62: 6615-6629 [PMID:31251063]
ChEMBL Inhibition of MANT-uracil binding to Magnetospirillum gryphiswaldense cereblon isoform 4 Y101F mutant by FRET assay B 4.97 pIC50 10700 nM IC50 J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL Inhibition of MANT-uracil binding to wild type Magnetospirillum gryphiswaldense cereblon isoform 4 by FRET assay B 5.11 pIC50 7800 nM IC50 J Med Chem (2016) 59: 770-774 [PMID:26730808]
Cyclooxygenase-1 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2949] [UniProtKB: P05979]
ChEMBL Inhibitory activity (RA1) against Prostaglandin G/H synthase 1 was calculated relative to aspirin B 6.43 pIC50 370 nM IC50 Bioorg Med Chem Lett (2002) 12: 1043-1046 [PMID:11909713]
Cyclooxygenase-2 in Sheep (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4102] [UniProtKB: P79208]
ChEMBL Inhibitory activity (RA2) against Prostaglandin G/H synthase 2 was calculated relative to aspirin B 6.3 pIC50 500 nM IC50 Bioorg Med Chem Lett (2002) 12: 1043-1046 [PMID:11909713]
cereblon/Protein cereblon in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3763008] [GtoPdb: 3086] [UniProtKB: Q96SW2]
GtoPdb Determined in a BiaCore assay using immobilised thalidomide and recombinant cereblon protein. - 8.07 pKd 8.5 nM Kd Science (2010) 327: 1345-50 [PMID:20223979]
ChEMBL Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by Cheng-Prusoff equation analysis B 4.64 pKi 22700 nM Ki J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence in presence of 0.5% DMSO by MST based assay B 5.07 pKi 8510 nM Ki ACS Med Chem Lett (2021) 12: 74-81 [PMID:33488967]
ChEMBL Inhibition of MANT-uracil binding to human CRBN (delta 1 to 315) by FRET assay B 4.52 pIC50 29900 nM IC50 J Med Chem (2016) 59: 770-774 [PMID:26730808]
ChEMBL Binding affinity to human CRBN-thalidomide binding domain expressed in Escherichia coli by measuring baseline corrected normalized fluorescence in presence of 0.5% DMSO by MST based assay B 4.64 pIC50 22900 nM IC50 ACS Med Chem Lett (2021) 12: 74-81 [PMID:33488967]
ChEMBL Displacement of fluorescent tracer from NanoLuc-tagged CRBN (unknown origin) by NanoBRET assay B 5.83 pIC50 1490 nM IC50 RSC Med Chem (2023) 14: 501-506 [PMID:36970148]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]